Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05754450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2026
    • Site contact updated
    v6
  2. Study Identification, Study Status, Oversight, Contacts/Locationsv5
  3. Lead sponsor: Avalo Therapeutics, Inc. to AUG Therapeutics
    • Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 21, 2023 to Apr 10, 2023
    • Site details revised
    v3
  5. Start date: Feb 21, 2023 to Apr 21, 2023v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
Trial Details
NCT Number NCT05754450
Lead Sponsor AUG Therapeutics
Conditions
(from sponsor)		 Leukocyte Adhesion Deficiency
Related terms Leukocyte adhesion deficiency type 1
Enrollment 2 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov